awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q37049104-8B9E8687-AB96-49DC-83CD-F6ADDF2D4AA7
Q37049104-8B9E8687-AB96-49DC-83CD-F6ADDF2D4AA7
BestRank
Statement
http://www.wikidata.org/entity/statement/Q37049104-8B9E8687-AB96-49DC-83CD-F6ADDF2D4AA7
Mechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular carcinoma
P2860
Q37049104-8B9E8687-AB96-49DC-83CD-F6ADDF2D4AA7
BestRank
Statement
http://www.wikidata.org/entity/statement/Q37049104-8B9E8687-AB96-49DC-83CD-F6ADDF2D4AA7
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
3dc2ef0dec66a84ba176562c9d3963f8b8dee0c6
P2860
Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma.